

PRESS RELEASE | ECULLY, FRANCE – March 14th, 2025

SEQENS and Novonesis announce strategic partnership for enhancing customer's access to industrial biocatalytic processes within the Fine Chemicals market.

The SEQENS Group, a global leader in health, personal care, and specialty ingredients, is excited to announce a strategic partnership with Novonesis, a world leader in sustainable biological solutions. Protéus teams within SEQENS* have developed a long-standing expertise in enzyme discovery, optimization, and production as well as biocatalytic process development and implementation. With the world's largest strain bank, a broad commercial portfolio and large-scale, state-of-the-art production facilities, Novonesis harness the power of enzymes to replace chemicals and metal catalysts, reduce waste and make industrial processes greener and more efficient.

This partnership will leverage the combined expertise of both companies to offer comprehensive screening of an extensive range of commercial enzymes from their respective catalogs.

SEQENS' long-standing expertise in developing associated biocatalytic processes, coupled with their robust manufacturing capabilities across various global locations, will ensure delivery of strong process books and efficient supply of desired reaction products.

Together, SEQENS and Novonesis are committed to driving advancements in biocatalysis, providing sustainable and cost-effective solutions, and enhancing the overall value proposition for their customers.

"This unique partnership between SEQENS and Novonesis finally brings together two industry leaders that will deliver innovative and competitive biocatalytic processes to the Fine Chemicals market" says Julien Boutet, Innovation & Biotechnologies Director at SEQENS.

"Novonesis and SEQENS, as strategic partners, will advance the Fine Chemical industry's commitment to sustainability and innovation by successfully commercializing biocatalytic concepts" says Hans Ole Klingenberg, Vice President, Global Marketing & Strategy, House Hold Care & Industrial at Novonesis.

About SEQENS:

SEQENS is a global partner in health, personal care and specialty ingredients, leveraging 3300 employees, 16 manufacturing sites and 9 R&D centers in 9 countries. As an integrated player across the entire value chain – from raw materials to active ingredients and from R&D to industrialization – SEQENS offers a broad portfolio of active pharmaceutical ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most complex molecules, and leverages its ability to innovate, develop and implement the best available technologies. Driven by a culture of excellence and a strong entrepreneurial spirit, the group shares values such as unity, agility, and reactivity. SEQENS provides the highest level of service and quality to more than 1500 customers around the world while acting ethically in accordance with its strong CSR program.

* SEQENS refers to the legal entity PCAS SAS

About Novonesis:

Novonesis is a global company leading the era of biosolutions. By leveraging the power of microbiology with science, we help transform the way the world produces, consumes and lives. In more than 30 industries, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology.

Novonesis was formed in 2024 when Chr. Hansen and Novozymes joined forces. Our biosolutions enable feeding and fueling the world more sustainably, and reduce the use of fossil-based resources, chemicals, energy and water. In Novonesis, we know that solutions rooted in biology can help solve humanity's biggest challenges. Now, more than ever, the world needs change. And with biosolutions, the possibilities for transformation are endless.

We're here to better our world with biology.

www.novonesis.com

press@seqens.com / www.seqens.com / LinkedIn : SEQENS

www.seqens.com

SEQENS SAS - 21 chemin de la Sauvegarde, 21 Ecully Parc - CS 33167 - 69134 ECULLY Cedex - Capital Social 226 890 746.63 euros - 444 465 736 00049
RCS Lyon - Tel : +33 (0)4 26 99 18 00 - Fax : +33 (0)4 26 99 18 38